GHK-Cu: a complete guide to the copper peptide

What GHK-Cu is (and what it is not)

GHK-Cu is the complex formed by the tripeptide glycyl-L-histidyl-L-lysine (GHK) and a copper(II) ion. Loren Pickart identified it in human serum in 1973, as an activity that prolonged the survival of normal liver cells in culture¹. According to his group's reviews, GHK is present in plasma, saliva and urine, and its plasma concentration falls from about 200 ng/mL at age 20 to about 80 ng/mL at age 60². That age-related decline is one reason the peptide drew so much interest in dermatology and regenerative medicine.

It helps to separate, from the start, four substances that the market and the literature often blur together: copper-free GHK (apo-GHK), GHK-Cu itself, its derivatives (such as palmitoyl-GHK) and other copper peptides that are not GHK. A 2026 systematic review stresses that the literature tends to treat GHK-Cu as a single active ingredient, even though its coordination state, speciation, stability and toxicity change with the formulation²². That distinction matters when reading any study, and we come back to it in the comparison below.

If you prefer an introduction without technical terms, see GHK-Cu, the copper peptide, without jargon. This guide gathers the essentials for physicians and links them to our deeper analyses.

GHK-Cu mechanism of action: four layers

The mechanism of GHK-Cu is well described in the laboratory. We summarize it in four layers; the full detail, study by study, is in GHK-Cu (copper peptide): the mechanism of action, step by step.

• Copper. During its isolation, GHK co-eluted with nearly equimolar copper, and the tripeptide increased uptake of the metal into cultured cells³. By calorimetry, the complex has a conditional dissociation constant of 7.0 × 10⁻¹⁴ M at pH 7.4, in a 1:1 ratio⁴. The original hypothesis was a copper carrier into cells.
• The extracellular matrix. In fibroblasts, GHK-Cu increased collagen synthesis with a peak at 10⁻⁹ M, without changing cell number⁵, and increased sulfated glycosaminoglycans⁶. In rat wound chambers, collagen and glycosaminoglycans increased⁷, and in rat wounds mRNA rose for decorin, the proteoglycan that organizes collagen fibers⁸.
• Remodeling. In dermal fibroblasts it increased MMP-2 and, at the same time, its inhibitors TIMP-1 and TIMP-2⁹. In ischemic rat wounds, by contrast, treated tissue had less MMP-2, MMP-9 and TNF-α, and wound area shrank by 64.5% at day 13 versus 45.6% with vehicle¹⁰. This is context-dependent modulation, not a simple increase or blockade.
• Cells, vessels, inflammation and genes. In keratinocytes it increased proliferation and the expression of p63 and integrins²⁹; KGHK peptides released from the protein SPARC stimulated angiogenesis³¹; in macrophages and in mice with lung injury it lowered reactive oxygen species, TNF-α and IL-6¹¹. Using the Connectivity Map tool, an independent team found that GHK reversed a gene signature of emphysematous destruction¹², and Pickart's group holds that GHK up- or downregulates at least 4,000 human genes²¹³.

Two caveats come with this mechanism. First, almost all of it comes from cell cultures and rats⁵⁷⁹¹⁰. Second, the gene data are computational analyses of cell-line profiles: they generate hypotheses, they do not show an effect in a person's skin¹²¹³.

What the human evidence shows

This is GHK-Cu's most important gap: a lot of biology and few trials. A 2025 review described "a surprising absence of clinical studies" with GHK-Cu and palmitoyl-GHK²⁰. A 2026 systematic review concluded that "the clinical literature in humans remains thin and fragmented"²¹. The controlled trials with GHK-Cu as the main agent are these:

• Diabetic neuropathic ulcers (1994). Multicenter, randomized, evaluator-blinded and vehicle-controlled. In plantar ulcers, the GHK-Cu gel achieved median area closure of 98.5% versus 60.8% with vehicle, and in plantar ulcers treated right after debridement, infection occurred in 7% versus 34%¹⁴.
• Venous ulcers (1992). Randomized, evaluator-blinded, 86 evaluable patients. The 0.4% copper tripeptide cream did not differ from placebo; 1% silver sulfadiazine was superior to both¹⁵.
• Skin after CO2 laser (2006). Randomized, 13 patients, 12 weeks. No objective differences in erythema, wrinkles or overall quality; subjective satisfaction was higher with the GHK-Cu products (P = .04)¹⁶.
• Sparse eyebrows (2026, conference proceedings). Randomized, double-blind, vehicle-controlled and split-face, 18 participants, 2% serum for 12 weeks: greater hair count and diameter on the treated side²⁸.

The balance is mixed and small. The 2026 review that mapped all the evidence up to August of that year considers the historical cosmetic studies small or poorly characterized, and notes that the eyebrow trial did not define GHK-Cu speciation or local exposure²². The only registered phase 2 trial, a GHK-Cu gel versus vehicle in standardized acute wounds with 60 planned participants, is still recruiting and has no results²⁵. Our critical analysis of those trials and of who writes the literature is in GHK-Cu: four decades of papers, few trials.

GHK-Cu and hair: what has been studied

Interest in the hair follicle comes mainly from ex vivo data. The most cited study used a sister molecule, AHK-Cu (alanyl-histidyl-lysine-copper): at 10⁻¹² to 10⁻⁹ M it elongated cultured human follicles and stimulated proliferation of dermal papilla cells¹⁷. Reviews from Pickart's group also list hair follicles among the tissues whose repair GHK would support²¹³.

In humans, the most direct controlled data are the eyebrow trial²⁸. A trial in 45 men with androgenetic alopecia used a complex of 5-aminolevulinic acid with GHK, with no copper stated, and saw a larger increase in hair count than placebo²⁷; that is not GHK-Cu and cannot be credited to it. We review the full set of peptides studied in hair in Peptides and hair loss: copper, thymosin β4 and biomimetics against the evidence.

GHK-Cu versus its relatives: how they compare

Much of the confusion about the copper peptide comes from crediting one molecule with another's data. This comparison sums up what is known about each:

• GHK-Cu (copper complex). The form with the most mechanistic data: collagen, glycosaminoglycans, decorin and MMP/TIMP⁵⁶⁸⁹. It has 4 controlled trials with mixed results^14151628. It is highly hydrophilic, which limits its passage through skin²⁰²³.
• Copper-free GHK (apo-GHK). In fibroblasts, the rise in MMP-2 was reproduced by copper alone but not by copper-free GHK⁹, and KGHK peptides stimulated angiogenesis without depending on bound copper³¹: each effect must be credited to the species that was measured.
• Palmitoyl-GHK (Pal-GHK). The derivative with a fatty chain that increases its permeability, widely used in anti-wrinkle creams; the 2025 review likewise found few clinical studies²⁰.
• AHK-Cu. Swaps glycine for alanine; its follicle data are ex vivo and do not automatically transfer to GHK-Cu¹⁷.
• Multi-ingredient formulas. Products with "copper tripeptide-1" alongside other actives make it impossible to know how much of the effect belongs to the peptide²².

GHK-Cu also appears in regenerative blends with other peptides; the logic of those combinations and their limits are in GLOW, KLOW and Wolverine: the logic of regenerative blends.

Reaching the dermis: topical, microneedles and injection

A mechanism only matters if the molecule reaches its site of action. GHK-Cu is highly hydrophilic: its distribution coefficient (log D) is between −2.38 and −2.49 at pH 4.5 to 7.4²³. In dermatomed human skin, under infinite-dose conditions over 48 hours, 136.2 µg/cm² of copper applied as the tripeptide permeated and 82 µg/cm² was retained; the method measured copper, not intact peptide¹⁸. Through intact human skin almost no peptide or copper passed in 9 hours; after microneedle pretreatment, 134 nmol of peptide and 705 nmol of copper permeated, with no obvious signs of irritation¹⁹.

That is why research has moved toward vehicles and devices: liposomes, nanocarriers, hydrophobic modification and microneedles²⁰²². The 2026 microneedle review stresses that this route has not yet been tested in an adequately powered randomized human trial published in a peer-reviewed journal²¹. The injectable route has the least data: we found no published human trials²²²⁴.

GHK-Cu safety and adverse effects

What is known about safety comes from small topical trials and laboratory models. In the diabetic ulcer trial, the treated group had fewer infections than the vehicle group in plantar ulcers treated after debridement¹⁴. In microneedle-pretreated skin, cell and porcine models showed no obvious signs of irritation¹⁹. None of these studies has the size or duration to detect rare or late effects.

For the injectable route, the FDA keeps injectable GHK-Cu on its list of nominated-and-withdrawn substances with potential safety risks. Its text says compounded injectables containing GHK-Cu "may pose risk for immunogenicity" "due to the potential for aggregation and peptide-related impurities," and that "there are limited data in humans to inform safety-related considerations"²⁴. The 2026 review adds that formulation studies almost never report labile copper (copper not firmly bound to the peptide) and proposes route-specific safety thresholds²².

Quality, stability and purity

The chemistry of GHK-Cu explains much of its quality problem. In a preformulation study using stability-indicating HPLC, the peptide degraded by hydrolysis under basic and oxidative conditions, and to a lesser extent acidic ones, with first-order kinetics; one of the three main degradation products was histidine²³. By contrast, it stayed stable in water and in pH 4.5 to 7.4 buffers for at least two weeks at 60 °C, and was less stable in the presence of the negatively charged lipid dicetyl phosphate²³. In other words: formulation pH and excipients matter.

Beyond peptide purity, the 2026 review proposes controlling parameters that almost no study reports: molar copper occupancy (how much of the peptide actually carries its copper), labile copper, speciation and release of the intact complex versus free GHK or free copper²². A Warsaw group developed in 2026 a capillary electrophoresis method coupled to ICP-MS/MS to track liposome-encapsulated GHK-Cu inside cosmetic emulsions and serums, in order to separate the species present in those complex matrices and detect the copper from the complex³⁰. To read a lot's certificate, see How to read a peptide certificate of analysis, and for reconstitution chemistry, Peptide stability: from lyophilized powder to reconstituted vial.

Open questions about GHK-Cu

• How much reaches the dermis intact? Permeation studies mostly measure copper, not the intact peptide¹⁸²².
• Which species produces each effect? GHK-Cu, copper-free GHK and free copper are not equivalent⁹²²³¹.
• Is there reproducible clinical benefit? Controlled trials are few, small and mixed; the phase 2 acute-wound trial has no results yet^14151625.
• Is the injectable route safe? There are no published human trials, and the FDA points to a potential immunogenicity risk²⁴.
• Who produces the evidence? Many of the most cited reviews come from the group that described the peptide, which has held commercial interests in the field for decades²¹³²⁶; a 2026 review estimates that about 35% of the primary literature includes that group and warns that this concentration limits the independence of the evidence²¹.